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AbstrACt
Purpose Multimorbidity is commonly defined and 
measured using condition counts. The UK National Institute 
for Health Care Excellence Guidelines for Multimorbidity 
suggest that a medication-orientated approach could be 
used to identify those in need of a multimorbidity approach 
to management.
Objectives To compare the accuracy of medication-based 
and diagnosis-based multimorbidity measures at higher 
cut-points to identify older community-dwelling patients 
who are at risk of poorer health outcomes.
Design A secondary analysis of a prospective cohort 
study with a 2-year follow-up (2010–2012).
setting 15 general practices in Ireland.
Participants 904 older community-dwelling patients.
Exposure Baseline multimorbidity measurements based 
on both medication classes count (MCC) and chronic 
disease count (CDC).
Outcomes Mortality, self-reported health related quality of 
life, mental health and physical functioning at follow-up.
Analysis Sensitivity, specificity, positive predictive values 
(PPV) and negative predictive values (NPV) adjusting 
for clustering by practice for each outcome using both 
definitions.
results Of the 904 baseline participants, 53 died during 
follow-up and 673 patients completed the follow-up 
questionnaire. At baseline, 223 patients had 3 or more 
chronic conditions and 89 patients were prescribed 10 or 
more medication classes. Sensitivity was low for both MCC 
and CDC measures for all outcomes. For specificity, MCC 
was better for all outcomes with estimates varying from 
88.8% (95% CI 85.2% to 91.6%) for physical functioning 
to 90.9% (95% CI 86.2% to 94.1%) for self-reported 
health-related quality of life. There were no differences 
between MCC and CDC in terms of PPV and NPV for any 
outcomes.
Conclusions Neither measure demonstrated high 
sensitivity. However, MCC using a definition of 10 or more 
regular medication classes to define multimorbidity had 
higher specificity for predicting poorer health outcomes. 
While having limitations, this definition could be used for 
proactive identification of patients who may benefit from 
targeted clinical care.
IntrODuCtIOn 
A high proportion of patients consulting in 
primary healthcare present with multimor-
bidity, defined generally as the presence of at 
least two chronic medical conditions.1 Multi-
morbidity has a significant impact across the 
age ranges but is more common in older 
patients and is associated with poorer quality 
of life,2 3 psychological distress,4–6 loss of phys-
ical function,7 polypharmacy and adverse 
drugs events8 and care duplication and incon-
sistencies.9 10 Within the broad multimor-
bidity population, outcomes are poorer in 
patients with more complex multimorbidity, 
which has been defined previously in terms 
of higher numbers of conditions or higher 
healthcare utilisation.
Even though associations with poorer health 
outcomes are clear, identifying older patients 
with multimorbidity who will benefit from 
a community-based intervention is difficult 
due to the heterogeneity of multimorbidity 
strengths and limitations of this study
 ► This study compares use of medication classes 
count with the more traditional method of chronic 
disease counts to define multimorbidity. This ap-
proach could be used proactively in the clinical set-
ting to identify higher risk people.
 ► Our study used a large dataset with robust data 
collection from electronic health records combined 
with linked national pharmacy claims data and a pa-
tient questionnaire for self-reported outcomes.
 ► This study only included older patients with multi-
morbidity, further research would be needed to vali-
date these results in other populations.
 ► This study is a secondary analysis and as such is 
limited to the data collected from the recruited pop-
ulation in the original cohort study.
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definitions and measures, used in both public health 
and clinical interventions.11 Existing trials have based 
inclusion on the number of conditions along with other 
markers of risk such as older age or high healthcare util-
isation.12 The UK National Institute for Health and Care 
Excellence (NICE) 2016 Guidance on Multimorbidity 
recommends that health practitioners should proactively 
identify patients that could benefit from a multimorbidity 
approach to clinical care. The NICE Guidance suggests 
considering a multimorbidity approach to care for adults 
of any age who are prescribed ≥10 medications with the 
advantage that this information can be retrieved from 
the electronic health record.13 This approach to care 
is patient-centred as it follows patient goals and pref-
erence of care, focusing on quality of life by reducing 
treatment burden, adverse events, and unplanned care 
and improving services coordination. Polypharmacy is a 
marker of multimorbidity and patients identified this way 
can be regarded as having multimorbidity and offered 
broad interventions beyond medicines management. 
For condition count multimorbidity measurement, the 
literature suggests using ≥3 chronic conditions to identify 
patients with higher needs.s14 15
This study aimed to examine the accuracy of medica-
tion-based versus condition count-based definitions of 
multimorbidity in predicting poorer health outcomes for 
older community-dwelling patients.
MEthODs
The Strengthening The Reporting of Observational 
Studies in Epidemiology guidelines were used to guide 
the conduct and reporting of this study.16
study design and population
This is a secondary analysis of a 2-year, prospective cohort 
study that was established to examine potentially inappro-
priate prescribing and adverse health outcomes in older 
community-dwelling patients.17 The study population was 
recruited from 15 randomly selected general practices 
in Leinster, Ireland for a 2-year (2010–2012) prospec-
tive cohort study involving older community-dwelling 
patients. Proportionate stratified sampling was carried 
out based on the overall required sample size and the 
total number of eligible patients per practice assuming 
a 50% response rate and of 3070 eligible patients, a total 
of 1764 were invited to participate.17 18 Of this group, 152 
were ineligible on invitation based on eligibility criteria 
and 125 were not contactable resulting in 1487 patients 
eligible for participation.
Study inclusion criteria
1. Age ≥70 years on 1 January 2010.
2. in receipt of a valid general medical services card, 
which is means tested and entitles the holder to free 
public medical services including general practitioner 
(GP) care.
Exclusion criteria
1. Receiving palliative care.
2. Cognitive impairment at the level that would affect 
their ability to complete the outcome measure (de-
fined as Mini Mental State Examination ≤20).
3. Significant hearing/speech/visual impairment.
4. Currently experiencing a psychotic episode.
5. Hospitalised long-term, in a nursing home, homeless 
or in sheltered accommodation.
6. Recent bereavement (within 4 weeks).
Of 1487 eligible and invited to participate at baseline 
(T0) a total of 904 (61%) agreed.17 18 Two study popu-
lations are presented depending on the outcome of 
interest:
a. Patients who either completed a 2-year follow-up (T1) 
or died before T1 for mortality analysis (n=726).
b. Patients who completed T1 self-reported question-
naires for patient reported health outcomes analysis 
(n=673).
Demographic data collected
Sociodemographic variables collected included age, 
deprivation, gender, social class, education, marital status 
and living arrangements. Age and gender were collected 
from the GP electronic medical record. The deprivation 
score was obtained with the geocoded patients address 
based on the Small Area Health Research Unit which 
uses electoral division.19 Education levels were classified 
as basic education (no formal education, primary educa-
tion or lower secondary education only) or upper and 
postsecondary (all other higher levels of education). 
Social class was classified as unskilled (unskilled, gain-
fully occupied, unknown) or skilled (all other catego-
ries). Marital status was classified as married, separated/
divorced, widowed and single/never married. Living 
arrangements were classified as living with husband/
wife/life partner, family/relatives, living alone and 
other.
Exposure of interest: multimorbidity measures
Two measures of multimorbidity were selected based on 
current guidelines and literature.14 15
Medication classes count (MCC)
The number of regular prescribed medication classes 
was calculated by linkage to the national Health Services 
Executive-Primary Care Reimbursement Scheme phar-
macy claims database. The number of medication classes 
prescribed to the patient were classified using the first 
three characters of the WHO-ATC classification system 
and the sample was divided using a cut-off definition of 
≥10 prescribed medication classes.20 The NICE guidelines 
indicate that a patient with ≥10 prescribed medicines and 
an additional risk factor would benefit from a multimor-
bidity approach.21 As all cohort participants were ≥70 
years, this population was considered as having an addi-
tional risk factor.
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Chronic disease count (CDC)
At baseline, chronic diseases were collected from the 
GP electronic medical record by eight trained medical 
students using standardised data collection forms. A 
disease count proposed by Barnett et al which includes 
40 chronic diseases on the basis of disease prevalence 
and severity was used to define multimorbidity.22 A cut-off 
of ≥3 chronic diseases was used to identify multimor-
bidity.14 15
Primary outcomes
Mortality and patient reported outcome measures 
(PROM) were selected to identify patients with poorer 
health at follow-up. The study examined poorer self-re-
ported health between T0 (baseline) and T1 (2 years). 
The PROMs were dichotomised, as described below to 
identify changes in outcome over the 2 years.
Mortality
Mortality was assessed by examining each participant’s 
GP electronic medical record. Where there was any query 
regarding the date of death, it was double checked using 
a national repository of deaths in Ireland.
Health-related quality of life
The Euro-Qual 5 Dimensions (EQ-5D) is a generic instru-
ment widely used to assess health-related quality of life 
by using ordinal scaling to assess fives domains: mobility, 
self-care, usual activities, pain/discomfort and anxiety/
depression. Poorer self-reported health was defined 
using the Paretian principles method described by Devlin 
et al.23 Following these principles, poorer health-related 
quality of life was operationalised as a decline in a greater 
number of domains scores compared with stable or 
improved domains scores.23
Mental health
The Hospital Anxiety and Depression Scale (HADS) is a 
measure assessing levels of anxiety and depression inde-
pendently, which are then classified as normal, mild, 
moderate or severe.24 Poorer self-reported mental health 
was defined as a higher score at follow up-compared with 
baseline according to the HADS.24
Physical functioning
The Vulnerable Elders Survey (VES-13) is a patient-re-
ported outcome measure used to identify older patients 
at risk of functional decline.25 In the derivation study 
for this tool, patients who scored ≥3 had four times the 
risk of death or functional decline over a 2-year period 
than patients who scored <3.25 Accordingly, patients were 
classified as having poorer self-reported health if study 
participants who scored l<3 at baseline (T0) scored ≥3 at 
follow-up (T1).
statistical analysis
Descriptive statistics are presented to describe patient 
characteristics. For categorical measures, the number 
of patients and percentage were calculated, and for 
continuous measures, the mean and SD. For continuous 
scales which showed evidence of, or were expected to 
show some skew, a median and interquartile range were 
presented. A Χ2 test, t-test or Mann-Whitney test was used 
as appropriate, adjusting for clustering by practice, to 
examine possible associations between patient character-
istics and multimorbidity measures (patients with ≥10 vs 
<10 prescribed medication classes and patients with ≥3 vs 
<3 chronic diseases).
The sensitivity, specificity, positive predictive values 
(PPV) and negative predictive values (NPV), along with 
95% CIs, were calculated adjusting for clustering by prac-
tice using Stata  V.15 (StataCorp. 2017) for each outcome 
and using both exposures of interest (MCC and CDC). 
For our analyses, sensitivity is the probability of a patient 
who experiences the health outcome of interest (ie, death 
or decline in PROM at follow-up) having multimorbidity 
at baseline, specificity is the probability of a patient who 
does not experience the health outcome at follow-up not 
having multimorbidity at baseline, the PPV is the proba-
bility of a patient with multimorbidity at baseline having 
the health outcome at follow-up and the NPV is the prob-
ability of a patient without multimorbidity at baseline not 
having the health outcome at follow-up.
risk of bias
The risk of bias was assessed in the cohort study using The 
Cochrane risk of bias tool for non-randomised studies.26
Patient and public involvement
This study is a secondary analysis of a cohort study which 
started enrolment in 2010. No patients or members of the 
public were involved in its design phase.
rEsults
Participants
A total of 223 participants (30.7%) met the criteria for 
the CDC definition for multimorbidity, and 89 patients 
(12.3%) met the criteria for the MCC definition. Overall, 
61 patients met both criteria. The median age of the total 
sample was 76.4 years, a total of 348 (47.9%) participants 
were men, 565 (77.8%) were classified as coming from the 
skilled social class and 433 (59.6%) reported a basic level 
of education. Descriptive characteristics of the patients 
identified by the CDC and the MCC cut-offs are presented 
in table 1. Patients with a disease count ≥3, compared 
with those with a disease count <3, were on average older 
and reported less formal education. Patients prescribed 
≥10 medications classes were on average older, women 
and had less formal education compared with patients 
prescribed <10 medication classes.
OutCOMEs
The proportion of patients defined as having multimor-
bidity using both definitions who died or reported poorer 
health outcomes are presented in table 2. Patients with 
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≥10 medication classes had a significantly higher mortality 
rate compared with patients with <10 medication classes 
(17% vs 6%, p<0.001). There was no difference in the 
other outcomes measured. Patients with a disease count 
of ≥3, compared with those with a disease count of <3, 
had a significantly higher decline in psychological well-
being (19.5% vs 11.7%, p=0.017) but there was no differ-
ence in any of the other outcomes.
The sensitivity, specificity, PPV and NPV along with 95% 
CIs adjusted for clustering by practice are presented in 
table 3 for both definitions of multimorbidity for each 
outcome of interest. For mortality, specificity was higher 
for MCC (89.0%; 95% CI 86.0% to 91.5%) compared 
with the CDC (70.3%; 95% CI 63.5% to 76.3%). For 
decline in health-related quality of life, both CDC and 
MCC measures had low sensitivity, however, the CDC 
(28.5%; 95% CI 22.1% to 35.9%) was higher than the 
MCC (10.5%; 95% CI 7.6% to 14.4%). In terms of speci-
ficity, MCC (90.9%; 95% CI 86.2% to 94.1%) was higher 
when compared with the CDC measure (71.9%; 95% CI 
64.8% to 78.1%).
Similar patterns were reported for decline in physical 
functioning and psychological functioning as were seen 
for decline in health-related quality of life. Specificity 
was moderate for the CDC measure for both decline in 
physical functioning (71.9%; 95% CI 64.8% to 78.1%) 
and decline in psychological functioning (71.1%; 95% CI 
64.6% to 76.9%). The MCC demonstrated higher spec-
ificity (decline in physical functioning: 88.8%; 95% CI 
85.2% to 91.6% and decline in psychological functioning: 
89.9%; 95% CI 86.2% to 92.7%).
risk of bias
The risk of bias is reported fully in the primary cohort 
study previously.17 Overall, the risk of bias was low 
regarding losses to follow-up. As this is a secondary anal-
ysis, exclusion of participants with cognitive impairment 
and the small sample of participants with ≥15 medication 
classes could reduce generalisability.26
DIsCussIOn
Main results
In this population of community-dwelling older patients, 
sensitivity was low for both the MCC and CDC measures 
for all outcomes. However, for self-reported health-re-
lated quality of life, psychological well-being and physical 
functioning at follow-up, the CDC measure was more 
sensitive. There was no difference in sensitivity between 
measures for the outcome of death. In terms of specificity, 
the MCC approach was better for all outcomes with esti-
mates varying from 88.8% (95% CI 85.2% to 91.6%) for 
physical functioning to 90.9% (95% CI 86.2% to 94.1%) 
for self-reported health-related quality of life.
With high specificity, the MCC definition has better 
potential to proactively ‘rule-in’ patients with multi-
morbidity who are more likely to have poorer health 
outcomes compared with the more widely used condi-
tion count approach. There are also fewer patients 
identified using the MCC definition, which is more 
manageable from a clinical or organisational perspec-
tive. However, both definitions had insufficient sensi-
tivity, showing a limited potential to accurately ‘rule out’ 
patient at risk of poorer health outcomes in this popula-
tion. Ideally a definition with both high sensitivity and 
specificity could be used to target multimorbidity inter-
ventions but existing risk stratification models have 
similar limitations.27
Table 2 Patients with multimorbidity according to MCC or CDC and outcomes of death, decline in health-related quality of 
life, decline in physical functioning and decline in psychological well-being
Outcome
MCC CDC
Patients with <10 
medications
Patients with ≥10 
medications
Cluster adjusted 
χ2p value
Patients with 
<3 chronic 
diseases
Patients with 
≥3 chronic 
diseases
Cluster adjusted 
Χ2 p value
Death (n=724) 
  No 598 (94.0%) 73 (83.0%) <0.001 472 (94.0%) 199 (89.6%) 0.054
  Yes 38 (6.0%) 15 (17.0%) 30 (6.0%) 23 (10.4%)
Decline in health-related quality of life (EQ-5D) (n=636) 
  No 393 (68.3%) 39 (63.9%) 0.443 310 (68.0%) 122 (67.8%) 0.820
  Yes 182 (31.7%) 22 (36.0%) 146 (32.0%) 58 (32.2%%)
Decline in physical functioning (VES-13) (n=673) 
  No 525 (87.7%) 66 (89.2%) 0.622 418 (88.4%) 173 (86.5%) 0.768
  Yes 74 (12.4%) 8 (10.8%) 55 (11.6%) 27 (13.5%)
Decline in psychological well-being (HADS) (n=649) 
  No 501 (86.7%) 56 (78.9%) 0.116 401 (88.3%) 156 (80.0%) 0.017
  Yes 77 (13.3%) 15 (21.1%) 53 (11.7%) 39 (19.5%)
CDC, chronic disease count; EQ5D, Euro-Qual 5 Dimensions; HADS, Hospital Anxiety and Depression Scale; MCC, medication classes 
count; VES-13, Vulnerable Elders Survey.
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strengths and limitations
In this cohort study, the MCC variable was obtained from 
linked national pharmacy claims data and the number 
of chronic diseases count was obtained via review of the 
participants’ electronic medical record, which adds to 
the robustness to the data used in this analysis. A main 
strength of the study is that the dataset includes a variety 
of outcomes including mortality and patient-reported 
outcomes.
The first limitation of this study is inherent to the 
secondary analysis design. By using previously collected 
data, it is not possible to align data collection directly with 
the goals of the current study, however we did have a wide 
range of patient reported and chart data available for 
analysis. The cohort study sample was limited to a commu-
nity-dwelling older people without cognitive, visual or 
hearing impairment. However, recent studies indicate 
that multimorbidity is not just a feature of ageing but is 
also prevalent in younger populations.1 28 29 We limited the 
number of chronic conditions identified in the records to 
40 prespecified conditions. Another potential limitation 
is the collection of data from medical records as there 
may have been some variation in recording of conditions. 
Medication classes were used as the predictor of interest 
as per the WHO-ATC classification system rather than 
individual medications. Further research is needed to 
validate our findings in larger samples
Comparison with existing literature
Previous studies have reported mixed results concerning 
the predictive power of multimorbidity definitions for 
different outcomes. Several studies have showed that 
a weighted diagnosis count, the Charlson index was an 
suitable measure to predict mortality30–32 However, a 
large cohort study (n=95 372) comparing six measure of 
multimorbidity reported that the number of prescribed 
medications was the most accurate multimorbidity 
measurement to predict future GP and practice nurses 
consultations and that it was also the second most accurate 
measure to predict mortality, just behind the Charlson 
index.33 A previous analysis of the current cohort study 
data compared five continuous count-based definitions 
of multimorbidity and reported poor discrimination in 
predicting hospital admissions and self-reported func-
tional decline for all multimorbidity measures, with the 
medication class-based definition performing margin-
ally better than diagnosis-based definitions.34 A previous 
study reported that using a ≥10 medication class cut-off to 
measure multimorbidity performed similarly to another 
risk score with low sensitivity and high specificity, when 
applied in clinical settings to predict cardiovascular 
disease risk.27 Our findings are build on this previous 
research, by comparing the predictive power of a medi-
cation class count definition against a disease count defi-
nition using pragmatic cut-off points and also examining 
a range of self-reported health outcomes in addition to 
mortality. Research to date has highlighted the limita-
tions of multimorbidity measures in predicting adverse 
events and work in this area is now expanding to include 
biomarkers in an effort to address these limitations.35 36
Implications for future research and clinical practice
Further research should assess the accuracy of multi-
morbidity measures in a larger range of primary care 
populations, including middle-aged patients with multi-
morbidity and older patients with cognitive decline. 
Larger sample sizes are needed to test the ≥15 medica-
tions cut-off measure for multimorbidity also recom-
mended as an alternative in the UK NICE Multimorbidity 
Guidance.21 In our study, there was little difference in 
medication and condition count measures in identifying 
older people at higher risk of poor health outcomes but 
MCC demonstrated higher specificity showing a slight 
difference in age, suggesting that the medication defi-
nition might better identify older people at higher risk. 
While it shares some limitations with other multimor-
bidity measures, clinicians and researchers can follow the 
expert consensus in the UK NICE Multimorbidity Guid-
ance recommendations by using MCC to identify higher 
risk patients with multimorbidity as it is easy to use and 
offers a pragmatic approach and potential for identifica-
tion of patients through prescribing or electronic health 
records.
COnClusIOns
This study shows that using two measures of multimor-
bidity, a MCC cut-off of ≥10 and a CDC of ≥3 chronic 
diseases had low sensitivity in relation to predicting 
mortality, self-reported health-related quality of life, 
mental health and physical functioning, although the CDC 
was slightly more sensitive for the majority of outcomes. 
The MCC approach demonstrated higher specificity for 
mortality and decline in health status, making it possible 
to rule-in a small sample of patients identified with a risk 
of poorer health outcomes with a low rate of false posi-
tives. However, the low sensitivity means that some of 
those identified as low risk may also experience poorer 
health outcomes.
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